ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

In Q2, the company submitted to the U.S. Food and Drug Administration (FDA) an Expanded Access Protocol (EAP) for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse ...

Expanded Access Protocol for ANKTIVA in the Treatment of Lymphopenia: The company also announced it has submitted to the FDA an EAP to make available ANKTIVA for the treatment of lymphopenia.

Rates of neutropenia, lymphopenia, and infections were lower in the patients receiving avacopan than those who were not.

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...